Wells Fargo downgraded Septerna (SEPN) to Equal Weight from Overweight with a $14 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on SEPN: Septerna discontinues SEP-786 Phase 1 clinical trial in hypoparathyroidism Nine new option listings on February 12th Septerna appoints Labrucherie as Chief Financial Officer
